poudre pour solution injectable/pour perfusion
Sponsors
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire De Nantes, UZ Leuven
Conditions
Bacteriemia producida por P. aeruginosa.Infective Endocarditispatients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infectionstaphylococcal endocarditis
Phase 3
Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the intensive care unit (PITAGORE)
RecruitingCTIS2024-511866-36-00
Start: 2023-03-11Target: 600Updated: 2025-12-02
Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
Not yet recruitingCTIS2024-518018-22-00
Target: 422Updated: 2025-08-28
Phase 4
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.
Not yet recruitingCTIS2023-508441-41-00
Target: 306Updated: 2025-07-25
Rapid Oral Switch in Infectious Endocarditis, the ROSIE trial
Not yet recruitingCTIS2025-524484-20-00
Target: 152Updated: 2026-02-06